Insight Molecular Diagnostics
IMDX
95 hedge funds and large institutions have $201M invested in Insight Molecular Diagnostics in 2021 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 37 increasing their positions, 28 reducing their positions, and 11 closing their positions.
619% more call options, than puts
Call options by funds: $1.28M | Put options by funds: $178K
55% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 11
32% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 28
6% more funds holding
Funds holding: 90 → 95 (+5)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0.06% less ownership
Funds ownership: 3.15% → 3.09% (-0.06%)
38% less capital invested
Capital invested by funds: $323M → $201M (-$122M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$3.47M |
| 2 |
DC
Defender Capital
Charlotte,
North Carolina
|
+$2.82M |
| 3 |
BC
Broadwood Capital
New York
|
+$2.64M |
| 4 |
MAG
Millrace Asset Group
Berwyn,
Pennsylvania
|
+$1.26M |
| 5 |
D.E. Shaw & Co
New York
|
+$771K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PGM
Parian Global Management
Pound Ridge,
New York
|
-$6M |
| 2 |
MS
Maven Securities
St Helier,
Jersey
|
-$2.73M |
| 3 |
BlackRock
New York
|
-$1.66M |
| 4 |
Millennium Management
New York
|
-$1.09M |
| 5 |
Northern Trust
Chicago,
Illinois
|
-$1M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
MLICM
101
Metropolitan Life Insurance Company (MetLife)
New York
| – | -$133K | -1,162 | Closed |
|
|
PCM
102
Pinz Capital Management
New York
| – | -$125K | -1,085 | Closed |
|
103
ProShare Advisors
Bethesda,
Maryland
| – | -$106K | -919 | Closed |
|
|
CSS
104
Cubist Systematic Strategies
Stamford,
Connecticut
| – | -$77K | -670 | Closed |
|
|
S
105
SignatureFD
Atlanta,
Georgia
| – | -$1K | -6 | Closed |
|
|
EI
106
Ellevest Inc
New York
| – | +$276 | +3 | New |
|
IMDX Hedge Fund Activity: Q3 2021 in Review
95 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Insight Molecular Diagnostics (IMDX) for Q3 2021, worth a combined $201M — down 38% from $323M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new IMDX positions and 11 closed out — a net gain of 6 holders — while 37 added to existing stakes and 28 trimmed.
The largest buyer was OrbiMed, adding an estimated $3.47M. The largest seller was Parian Global Management, exiting entirely with an estimated $6M sold.
- 95 institutional investors held Insight Molecular Diagnostics (IMDX) as of Q3 2021, up from 90 in Q2 2021.
- Funds reported $201M of Insight Molecular Diagnostics stock for Q3 2021, down 38% quarter-over-quarter.
- 17 funds opened new Insight Molecular Diagnostics positions in Q3 2021 and 11 closed out, a net change of +6 holders.
- The largest Insight Molecular Diagnostics buyer in Q3 2021 was OrbiMed, an estimated $3.47M added.
- The largest Insight Molecular Diagnostics seller in Q3 2021 was Parian Global Management, an estimated $6M sold.
Based on aggregated 13F filings for Q3 2021.